Resverlogix

Resverlogix ROA

The Return on Assets (ROA) of Resverlogix (RVX.TO) as of Oct 25, 2026 is -99.61 %. In the previous year, Return on Assets (ROA) was -103.96 % — a change of -4.18% (higher).

ROA

-99.61 %

YoY

-4.18%

Last updated:

In 2025, Resverlogix's return on assets (ROA) was -99.61 %, a -4.18% increase from the -103.96 % ROA in the previous year.

The Resverlogix ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-1.00 USD
Jan 1, 2019
1,037.31 USD
Jan 1, 2020
0.02 USD
Jan 1, 2021
-248.16 USD
Jan 1, 2022
-44.49 USD
Jan 1, 2023
-255.00 USD
Jan 1, 2024
-103.96 USD
Jan 1, 2025
-99.61 USD
The Resverlogix ROA history
YEARROAYoY
-99.61 %-4.18%
-103.96 %-59.23%
-255.00 %+473.23%
-44.49 %-82.07%
-248.16 %-1.08 M%
0.02 %-100.00%
1,037.31 %-103,876.76%
-1.00 %-99.86%
-704.40 %+65.65%
-425.23 %+764.85%
-49.17 %-156.77%
86.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resverlogix Stock analysis

What does Resverlogix do? Resverlogix Corp is a biopharmaceutical company based in Canada that specializes in the research and development of innovative therapies for cardiovascular diseases. It was founded in 2001 by Dr. Donald J. McCaffrey and has been listed on the Toronto Stock Exchange since 2006. The company focuses on the development of synthetic molecules with the same potential as Resveratrol, a natural compound found in red grapes and wine, for the treatment of cardiovascular diseases. Resverlogix Corp follows an innovative business model that involves identifying disease-causing factors and developing targeted molecules to influence them, with the goal of developing effective therapies for patients with cardiovascular diseases. The company specializes in the development of therapeutic agents for atherosclerosis and diabetic nephropathy, and currently has two main products in clinical development: Apabetalone for the treatment of atherosclerosis and BAC25 for diabetic nephropathy. Apabetalone acts directly on the genome of cells and influences the gene expression of proteins relevant to the development of atherosclerosis, while BAC25 targets glucose and lipid metabolism in the kidney to slow down or prevent the development of diabetic nephropathy. Overall, Resverlogix Corp is a biopharmaceutical company focused on innovative therapies for cardiovascular diseases, with a business model based on identifying disease-causing factors and developing synthetic molecules to target them. Resverlogix is one of the most popular companies on Eulerpool.

ROA Details

Understanding Resverlogix's Return on Assets (ROA)

Resverlogix's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Resverlogix's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Resverlogix's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Resverlogix’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Resverlogix stock

Return on Assets (ROA) of Resverlogix is -99.61 % in 2025.

Return on Assets (ROA) of Resverlogix changed from -103.96 % to -99.61 %, representing a -4.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Resverlogix since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Resverlogix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Resverlogix

All Key Metrics — Resverlogix